Your browser is no longer supported. Please, upgrade your browser.
Settings
BMRN BioMarin Pharmaceutical Inc. daily Stock Chart
BMRN [NASD]
BioMarin Pharmaceutical Inc.
Index- P/E- EPS (ttm)-0.46 Insider Own0.40% Shs Outstand177.94M Perf Week-6.38%
Market Cap14.80B Forward P/E283.82 EPS next Y0.29 Insider Trans-17.90% Shs Float177.57M Perf Month-7.56%
Income-81.80M PEG- EPS next Q-0.20 Inst Own- Short Float5.30% Perf Quarter-14.72%
Sales1.49B P/S9.92 EPS this Y-1.80% Inst Trans0.13% Short Ratio9.58 Perf Half Y-21.55%
Book/sh16.68 P/B4.99 EPS next Y169.00% ROA-1.70% Target Price119.87 Perf Year-1.49%
Cash/sh6.09 P/C13.65 EPS next 5Y47.20% ROE-2.70% 52W Range79.13 - 106.74 Perf YTD-2.34%
Dividend- P/FCF- EPS past 5Y19.40% ROI-1.50% 52W High-22.09% Beta1.52
Dividend %- Quick Ratio2.90 Sales past 5Y22.10% Gross Margin78.90% 52W Low5.09% ATR2.77
Employees2849 Current Ratio3.90 Sales Q/Q-1.40% Oper. Margin-8.30% RSI (14)35.79 Volatility4.32% 3.00%
OptionableYes Debt/Eq0.28 EPS Q/Q60.40% Profit Margin-5.20% Rel Volume2.15 Prev Close82.35
ShortableYes LT Debt/Eq0.28 EarningsApr 25 AMC Payout- Avg Volume982.52K Price83.16
Recom1.80 SMA20-7.49% SMA50-9.18% SMA200-12.97% Volume2,109,611 Change0.98%
Apr-09-19Resumed Raymond James Outperform
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Dec-14-18Initiated Wolfe Research Outperform
Oct-01-18Initiated Cantor Fitzgerald Overweight $126
Aug-07-18Reiterated Stifel Buy $109 → $114
Aug-03-18Reiterated Stifel Buy $102 → $109
May-16-18Initiated Canaccord Genuity Buy $101
Jan-18-18Resumed Credit Suisse Outperform $113
Oct-06-17Resumed Goldman Buy $129
Sep-15-17Initiated RBC Capital Mkts Sector Perform $93
Sep-14-17Initiated Piper Jaffray Overweight $113
Aug-31-17Initiated Citigroup Buy $98
Aug-17-17Initiated Evercore ISI Outperform $100
Mar-30-17Initiated UBS Neutral $92
Mar-02-17Initiated Instinet Neutral $93
Feb-07-17Initiated Morgan Stanley Overweight $110
Jan-23-17Resumed Credit Suisse Outperform
Dec-08-16Initiated Gabelli & Co Buy $109
Nov-07-16Downgrade Piper Jaffray Overweight → Neutral
Nov-03-16Initiated Deutsche Bank Buy $106
Apr-18-19 10:33AM  Earnings Preview: BioMarin Pharmaceutical (BMRN) Q1 Earnings Expected to Decline Zacks
Apr-17-19 11:18AM  Forbes Names BioMarin 4th Best Midsize Employer in America PR Newswire -6.96%
10:06AM  As Nasdaq 100 hits record, Apple and Intel could still be buys, says expert CNBC
Apr-16-19 10:51AM  New Strong Sell Stocks for April 16th Zacks
Apr-12-19 07:06AM  8 Stocks May Jump on Takeovers as Market Nears Peak Investopedia
Apr-10-19 07:25AM  FireEye joins major Bay Area employers like Facebook, Netflix, Google, Microsoft and Salesforce in paying a typical worker more than $150,000 per year American City Business Journals
Apr-03-19 08:13AM  Does Sangamo Have the Best Gene Therapy Program Now? Motley Fool
Apr-02-19 09:56AM  Elon Musks CEO pay-to-worker ratio is the highest ever recorded how it compares at other tech companies American City Business Journals
08:30AM  BioMarin to Host First Quarter 2019 Financial Results Conference Call and Webcast on Thursday, April 25 at 4:30pm ET PR Newswire
Mar-31-19 07:57PM  Were Hedge Funds Right About BioMarin Pharmaceutical Inc. (BMRN) ? Insider Monkey
Mar-29-19 11:15AM  New Strong Sell Stocks for March 29th Zacks
Mar-28-19 03:29PM  Time to buy biotech and pharma stocks Reuters Videos
Mar-27-19 10:03AM  New Strong Sell Stocks for March 27th Zacks
09:15AM  S&P Fights Past Growth Concerns to Reclaim 2800 Zacks
Mar-25-19 10:10AM  3 Stocks to Buy Ahead of the Next Market Crash Motley Fool
Mar-23-19 09:30AM  Why Is BioMarin (BMRN) Down 0.9% Since Last Earnings Report? Zacks
Mar-20-19 04:55PM  S.F. hotel demand bubbles over, spilling out into the rest of the Bay Area American City Business Journals
Mar-18-19 10:47AM  New Strong Sell Stocks for March 18th Zacks
Mar-13-19 09:15AM  Boeing Keeps Dow from Joining Rally Zacks
Mar-08-19 11:09AM  Did BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Insiders Sell Shares? Simply Wall St.
Mar-07-19 07:50AM  New Strong Sell Stocks for March 7th Zacks
Mar-06-19 08:30AM  BioMarin to Participate in Cowen and Company 39th Annual Health Care Conference on March 12 in Boston PR Newswire
Mar-05-19 07:30AM  The $200K Club: Broadcom joins these Bay Area tech companies paying a typical employee top dollar American City Business Journals
Mar-01-19 09:29PM  Why Big Pharma Is Diving Into Gene Therapy Barrons.com
07:28AM  BioMarin Receives Positive CHMP Opinion in Europe for Palynziq® (pegvaliase Injection) for Treatment of Patients with Phenylketonuria (PKU) Aged 16 and Older PR Newswire
Feb-28-19 10:54AM  Sarepta (SRPT) Q4 Earnings Lag Estimates, Exondys 51 Sales Up Zacks
Feb-26-19 03:26PM  BioMarin Revenue Slips, but Big Picture Looks Dandy Motley Fool
07:30AM  Behind the Seizure Program Expansion Helps Speed the Diagnosis of Genetic Epilepsy in Younger Children Experiencing Unprovoked Seizures PR Newswire
07:19AM  2 More Gene Therapy Stocks on Big Pharma's Buyout Radar Motley Fool
Feb-25-19 03:12PM  Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal Benzinga
09:21AM  MarketPulse: Roche's Bumper Deal for Spark Therapeutics Boosts Healthcare Stocks Investing.com
Feb-24-19 08:00PM  Edited Transcript of BMRN earnings conference call or presentation 21-Feb-19 9:30pm GMT Thomson Reuters StreetEvents
10:46AM  Biogen, BioMarin, Lilly and Bristol-Myers Could Be in Crosshairs of Acquirers GuruFocus.com
Feb-22-19 04:21PM  Can This Biotech Stock Redeem Its Sales Lag With A Strong Gene Therapy? Investor's Business Daily
10:12AM  BioMarin Pharmaceutical Inc. (BMRN) Q4 2018 Earnings Conference Call Transcript Motley Fool
09:23AM  BioMarin (BMRN) Q4 Earnings & Sales Miss, Shares Decline Zacks
08:50AM  The Daily Biotech Pulse: BioMarin Slips On Earnings, TherapeuticsMD Posts In-Line Results, Orchard To Present Immunodeficiency Drug Data Benzinga
Feb-21-19 05:09PM  BioMarin: 4Q Earnings Snapshot Associated Press
04:05PM  BioMarin Announces Full Year and Fourth Quarter 2018 Results PR Newswire
Feb-17-19 08:14AM  FOMC minutes, Walmart earnings What to know in the week ahead Yahoo Finance
Feb-15-19 07:30AM  The typical Facebook employee earns double Silicon Valley's median household income. How 50+ big tech employers compare American City Business Journals
Feb-14-19 10:31AM  BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Feb-13-19 08:25AM  Market Trends Toward New Normal in Brighthouse Financial, BioMarin Pharmaceutical, EZCORP, Assembly Biosciences, A-Mark Precious Metals, and American Public Education Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
Feb-09-19 08:16AM  Is Sangamo's Gene-Editing Approach a Bust? Motley Fool
Feb-08-19 09:17AM  The Daily Biotech Pulse: Big Miss For Seattle Genetics; Hematology Conference Presentations; Gossamer Bio, Harpoon IPOs Benzinga
Feb-07-19 04:28PM  BioMarin Announces Ongoing Study Demonstrates Durable Treatment Benefit from Brineura® (cerliponase alfa) for 3 Years PR Newswire
Feb-04-19 08:35AM  BioMarin Announces 14 Presentations at 15th Annual WORLDSymposium 2019 PR Newswire
Feb-03-19 02:04PM  3 Gene Therapy Stocks With Huge Catalysts in 2019 Motley Fool
Jan-30-19 05:00AM  Biotech Conference Highlights Pipeline at BioMarin MoneyShow
Jan-29-19 01:18PM  Is BioMarin Pharmaceutical Inc.s (NASDAQ:BMRN) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
Jan-23-19 08:30AM  BioMarin to Host Fourth Quarter and Full Year 2018 Financial Results Conference Call and Webcast on Thursday, February 21 at 4:30pm ET PR Newswire
Jan-17-19 03:07PM  6 Stocks Beating the Market GuruFocus.com
Jan-15-19 07:30AM  This is how much Apple pays a typical employee and how that compares to Google, Facebook, Netflix, Microsoft, Box and more American City Business Journals
Jan-14-19 10:40AM  Is BioMarin Pharmaceutical Stock a Bargain? Motley Fool
Jan-11-19 10:59AM  Why Sarepta Therapeutics Stock Is Starting to Shine Again InvestorPlace
Jan-10-19 12:07PM  5 Biotech Stocks That Could Face M&A Next! InvestorPlace
Jan-09-19 07:39AM  The Daily Biotech Pulse: BioMarin Trims Outlook, MediciNova Enrolls First Patient In Brian Cancer Drug Study Benzinga
Jan-07-19 11:55AM  BioMarin Highlights Key Milestones for 2019 at 37th Annual J.P. Morgan Healthcare Conference in San Francisco PR Newswire
Jan-06-19 09:32AM  Outlook For Battered Biotech Stocks In 2019 Investopedia
Dec-18-18 08:55AM  Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved Benzinga
08:30AM  BioMarin to Present at 37th Annual J.P. Morgan Healthcare Conference in San Francisco PR Newswire
Dec-16-18 03:07AM  Argentiere Capitals Returns, AUM and Holdings Insider Monkey
Dec-13-18 05:18PM  Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay American City Business Journals
Dec-12-18 07:59AM  Is BioMarin Pharmaceutical Inc.s (NASDAQ:BMRN) CEO Paid Enough Relative To Peers? Simply Wall St.
Dec-10-18 07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
Dec-09-18 09:48AM  Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. (BMRN) Insider Monkey
Dec-07-18 07:30AM  Analysis: Positioning to Benefit within BioMarin Pharmaceutical, Ritchie Bros. Auctioneers, ADTRAN, Aspen Technology, AMC Entertainment, and Halliburton Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Dec-06-18 09:20AM  Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger Zacks
Dec-03-18 01:47PM  BioMarin Promotes Amy Wireman to Group Vice President, Human Resources PR Newswire
08:30AM  BioMarin to Participate in Citi's 13th Annual Biotech Conference on December 5 in New York City PR Newswire
Nov-29-18 05:45PM  Bayer will shift hemophilia drug work to Berkeley, but won't add jobs American City Business Journals
04:00PM  Why Catalyst Pharmaceuticals Stock Is Sinking Today Motley Fool
01:39PM  Bayer To Cut 12,000 Jobs Amid Strategic Overhaul To Focus On Pharma Investor's Business Daily
Nov-28-18 06:23PM  U.S. FDA approves Catalyst Pharma's rare disease drug Reuters
Nov-23-18 09:03AM  Sarepta Stock More Than Doubles This Year So Far: Here's Why Zacks
Nov-21-18 02:05PM  BioMarin sets stage early for haemophilia cure off-Broadway Reuters
01:54PM  RPT-FOCUS-BioMarin sets stage early for hemophilia cure off-Broadway Reuters
01:01AM  FOCUS-BioMarin sets stage early for hemophilia cure off-Broadway Reuters
Nov-16-18 08:22AM  A grandpa's hope for hemophilia cure leads him to gene therapy clinical trial CNBC
Nov-14-18 08:19AM  Sangamo stock drops after J.P. Morgan downgrade MarketWatch
Nov-12-18 02:30PM  BioMarin and Believe Limited Announce the Debut of 'Hemophilia: The Musical' PR Newswire
Nov-08-18 08:30AM  BioMarin to Participate in Two Investor Conferences in November PR Newswire
08:00AM  10 Health Care Stocks Seen Jumping on Takeovers Investopedia
Nov-07-18 09:10AM  BioMarin Highlights Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York PR Newswire
Nov-01-18 08:30AM  BioMarin to Highlight Breadth of Innovative Development Pipeline at R&D Day on November 7th in New York PR Newswire +5.73%
Oct-31-18 10:07AM  BioMarin Keeps on Pace for Its $2 Billion Goal Motley Fool
Oct-30-18 08:20AM  Research Report Identifies Deckers Outdoor, Navient, Phillips 66, BioMarin Pharmaceutical, McKesson, and Equity Residential with Renewed Outlook Fundamental Analysis, Calculating Forward Movement GlobeNewswire
Oct-27-18 02:06AM  Edited Transcript of BMRN earnings conference call or presentation 25-Oct-18 8:30pm GMT Thomson Reuters StreetEvents
Oct-26-18 01:05PM  BioMarin (BMRN) Q3 Earnings & Revenues Surpass Estimates Zacks
08:17AM  The Daily Biotech Pulse: Gilead's Q2, Syndax Breast Cancer Drug Setback, Synergy Pharma On Brink Of Default Benzinga
02:51AM  Biomarin Pharmaceutical Inc (BMRN) Q3 2018 Earnings Conference Call Transcript Motley Fool
Oct-25-18 05:29PM  BioMarin: 3Q Earnings Snapshot Associated Press
04:05PM  BioMarin Announces Third Quarter 2018 Results PR Newswire
Oct-22-18 07:30AM  Microsoft's typical worker makes $168K a year how that compares with Facebook, Google, PayPal, Box, Salesforce, Intel and other big Bay Area tech employers American City Business Journals
06:00AM  3 Biotech Stocks Poised to Rise by 15% or More Investopedia
Oct-21-18 05:15PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs Benzinga
Oct-17-18 08:00AM  Today's Research Reports on Trending Tickers: BioMarin Pharmaceutical and Tesaro ACCESSWIRE
Oct-16-18 12:57PM  BioMarin Receives Milestone Payments from Pfizer for Talzenna® (Talazoparib) for Metastatic Breast Cancer Patients with an Inherited BRCA Mutation PR Newswire +6.60%
Oct-11-18 05:16PM  BioMarin and Believe Limited Announce Selection of 25 High School Students to Perform in First-of-its-Kind 'Hemophilia: The Musical' PR Newswire
04:03PM  Forbes Names BioMarin Among World's Best Employers PR Newswire
BioMarin Pharmaceutical Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme to treat mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with mucopolysaccharidosis VI; Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme for adult patients with PKU; Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis IV Type A, a lysosomal storage disorder; and Firdapse for lambert eaton myasthenic syndrome. Its clinical and pre-clinical product pipeline includes valoctocogene roxaparvovec, an adeno associated virus vector drug development candidate in patients with severe hemophilia A; and vosoritide, a peptide therapeutic for the treatment of achondroplasia, a form of disproportionate short stature in humans. The company serves specialty pharmacies; and end-users, such as hospitals and foreign government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has collaboration and license agreements with Sarepta Therapeutics and Asubio Pharma Co., Ltd. The company was founded in 1996 and is headquartered in San Rafael, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BIENAIME JEAN JACQUESChief Executive OfficerApr 16Option Exercise21.511,00021,510326,211Apr 18 07:25 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 12Option Exercise14.394,00057,560329,211Apr 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 12Sale89.124,000356,480325,211Apr 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 11Option Exercise14.391,00014,390325,211Apr 15 08:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 08Option Exercise14.393,00043,170327,211Apr 09 06:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 08Sale91.873,000275,598324,211Apr 09 06:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Option Exercise14.393,00043,170327,211Apr 09 06:10 PM
Mueller BrianSVP, Corporate ControllerApr 05Sale94.002,953277,58213,660Apr 09 06:12 PM
BIENAIME JEAN JACQUESChief Executive OfficerApr 05Sale93.373,000280,114324,211Apr 09 06:10 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerApr 01Sale89.0013,4731,199,09747,510Apr 03 01:17 PM
LAWLIS V BRYANDirectorMar 27Option Exercise14.392,15030,93921,310Mar 29 06:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 27Option Exercise14.391,00014,390324,211Mar 29 06:07 PM
SPIEGELMAN DANIEL KEVP, Chief Financial OfficerMar 27Sale90.001009,00060,983Mar 29 06:19 PM
LAWLIS V BRYANDirectorMar 27Sale89.762,150192,98419,160Mar 29 06:30 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 26Sale89.183,656326,02547,475Mar 27 05:59 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 25Option Exercise14.394,00057,560327,211Mar 26 07:51 PM
FUCHS HENRY JPresident, Worldwide R&DMar 25Sale87.865,932521,186124,536Mar 26 08:20 PM
Davis George EricEVP, General CounselMar 25Sale87.863,363295,47371,890Mar 26 08:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 25Sale87.864,000351,440323,211Mar 26 07:51 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 21Sale89.984,519406,63454,729Mar 25 05:18 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 19Option Exercise14.391,00014,390336,338Mar 21 05:01 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerMar 19Sale93.073,728346,96559,248Mar 21 05:00 PM
Davis George EricEVP, General CounselMar 19Sale93.927,907742,62578,562Mar 21 05:00 PM
FUCHS HENRY JPresident, Worldwide R&DMar 18Sale94.099,597902,982136,304Mar 19 08:15 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Option Exercise14.394,00057,560339,338Mar 19 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 15Sale94.404,000377,600335,338Mar 19 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Option Exercise14.393,00043,170331,701Mar 14 02:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 13Sale93.423,000280,253328,701Mar 14 02:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Option Exercise14.394,00057,560332,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 12Sale91.444,000365,770328,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Option Exercise14.395,00071,950333,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 11Sale88.965,000444,780328,701Mar 13 08:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 07Option Exercise14.394,00057,560332,701Mar 08 08:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerMar 07Sale90.784,000363,120328,701Mar 08 08:34 PM
FUCHS HENRY JPresident, Worldwide R&DMar 04Sale95.002,196208,620142,504Mar 06 05:45 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 27Option Exercise14.394,00057,560292,290Feb 28 08:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 27Sale91.784,000367,120288,290Feb 28 08:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 21Option Exercise14.393,00043,170291,290Feb 22 06:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 21Sale90.123,000270,360288,290Feb 22 06:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 14Option Exercise14.394,00057,560292,290Feb 15 07:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 14Sale95.204,000380,800288,290Feb 15 07:06 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 05Option Exercise14.394,00057,560292,290Feb 07 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerFeb 05Sale98.634,000394,520288,290Feb 07 07:21 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 22Option Exercise14.393,00043,170291,290Jan 24 07:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 22Sale96.823,000290,460288,290Jan 24 07:07 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Option Exercise14.394,00057,560292,290Jan 15 07:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 14Sale93.794,000375,160288,290Jan 15 07:43 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Option Exercise14.393,00043,170291,290Jan 11 03:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 10Sale90.553,000271,650288,290Jan 11 03:30 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Option Exercise14.396,00086,340294,290Jan 10 06:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 08Sale91.596,000549,523288,290Jan 10 06:50 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Option Exercise14.393,00043,170291,290Jan 09 02:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerJan 07Sale87.583,000262,740288,290Jan 09 02:55 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Option Exercise14.393,00043,170291,290Jan 02 05:24 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 28Sale84.043,000252,120288,290Jan 02 05:24 PM
LAWLIS V BRYANDirectorDec 27Option Exercise14.392,15030,93921,310Dec 28 06:23 PM
LAWLIS V BRYANDirectorDec 27Sale82.532,150177,44019,160Dec 28 06:23 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Option Exercise14.394,00057,560292,290Dec 27 05:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 26Sale80.504,000322,000288,290Dec 27 05:35 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 14Option Exercise17.862,00035,720290,290Dec 18 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 14Sale92.642,000185,280288,290Dec 18 07:58 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 12Option Exercise17.862,00035,720290,290Dec 14 02:44 PM
BIENAIME JEAN JACQUESChief Executive OfficerDec 12Sale93.122,000186,240288,290Dec 14 02:44 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerNov 14Option Exercise63.109,000567,90058,135Nov 16 07:14 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerNov 14Sale92.159,000829,35949,135Nov 16 07:14 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 02Option Exercise17.861,50026,790289,790Nov 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 02Sale97.881,500146,820288,290Nov 05 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 01Option Exercise14.394,00057,560292,290Nov 02 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerNov 01Sale92.554,000370,200288,290Nov 02 05:34 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 30Option Exercise14.391,00014,390288,290Nov 01 07:26 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 24Option Exercise14.391,00014,390287,290Oct 26 06:08 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 03Option Exercise17.861,50026,790287,790Oct 05 05:42 PM
Ajer Jeffrey RobertEVP, Chief Commercial OfficerOct 03Sale98.981,00098,98549,135Oct 05 06:01 PM
BIENAIME JEAN JACQUESChief Executive OfficerOct 03Sale99.361,500149,040286,290Oct 05 05:42 PM
LAWLIS V BRYANDirectorSep 27Option Exercise14.392,15030,93921,310Sep 28 07:02 PM
LAWLIS V BRYANDirectorSep 27Sale97.932,150210,55019,160Sep 28 07:02 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 25Option Exercise14.391,00014,390286,290Sep 27 01:58 PM
Davis George EricEVP, General CounselSep 14Sale99.452,216220,38672,734Sep 18 04:42 PM
MEIER RICHARD ADirectorSep 13Option Exercise21.5115,000322,65084,610Sep 17 07:22 PM
MEIER RICHARD ADirectorSep 13Sale99.243,000297,72281,610Sep 17 07:22 PM
Davis George EricEVP, General CounselSep 13Sale99.5712,0001,194,84074,950Sep 17 06:57 PM
HERON ELAINE JDirectorSep 05Sale96.941,00096,93541,685Sep 07 02:00 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 04Option Exercise17.861,50026,790286,790Sep 06 05:41 PM
BIENAIME JEAN JACQUESChief Executive OfficerSep 04Sale98.161,500147,240285,290Sep 06 05:41 PM
LEWIS ALANDirectorAug 28Option Exercise14.397,500107,92528,660Aug 30 01:55 PM
LEWIS ALANDirectorAug 28Sale99.117,500743,32721,160Aug 30 01:55 PM
MEIER RICHARD ADirectorAug 27Option Exercise14.3915,000215,85071,610Aug 29 03:51 PM
MEIER RICHARD ADirectorAug 27Sale100.122,000200,23569,610Aug 29 03:51 PM
FUCHS HENRY JPresident, Worldwide R&DAug 27Sale100.0012,5001,250,000130,167Aug 28 05:54 PM
FUCHS HENRY JPresident, Worldwide R&DAug 24Sale99.0012,5001,237,500142,667Aug 28 05:54 PM
LEWIS ALANDirectorAug 21Sale100.094,200420,36521,160Aug 22 07:06 PM
Mueller BrianSVP, Corporate ControllerAug 07Option Exercise28.232,50070,57514,875Aug 09 04:27 PM
BAFFI ROBERTEVP, Technical OperationsAug 07Sale105.005,173543,16571,882Aug 09 04:58 PM
Mueller BrianSVP, Corporate ControllerAug 07Sale104.502,500261,25012,375Aug 09 04:27 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 23Option Exercise17.861,50026,790286,790Jul 25 07:47 PM
BIENAIME JEAN JACQUESChief Executive OfficerJul 23Sale101.691,500152,535285,290Jul 25 07:47 PM
LAWLIS V BRYANDirectorJun 27Option Exercise14.392,15030,93921,310Jun 29 05:59 PM
LAWLIS V BRYANDirectorJun 27Sale93.522,150201,06819,160Jun 29 05:59 PM
Mueller BrianSVP, Corporate ControllerJun 22Option Exercise28.232,49170,32114,866Jun 26 08:15 PM
BAFFI ROBERTEVP, Technical OperationsJun 22Option Exercise14.396,94999,99690,225Jun 26 08:23 PM